"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
(Generic versions may still be available.)
PROVISC (sodium hyaluronate) Viscoelastic Preparation is extremely well-tolerated after injection into human eyes during ophthalmic surgical procedures. As with most viscoelastic ophthalmic preparations, a transient rise in intraocular pressure has been reported in some cases.
Postoperative inflammatory reactions such as hypopyon and iritis have been reported with the use of ophthalmic viscoelastic preparations, as well as incidents of corneal edema and corneal decompensation. Their relationship to the use of sodium hyaluronate (PROVISC (sodium hyaluronate) ) has not been established.
Read the Provisc (sodium hyaluronate) Side Effects Center for a complete guide to possible side effects
No information provided.
Last reviewed on RxList: 2/15/2005
This monograph has been modified to include the generic and brand name in many instances.
Additional Provisc Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.